Pharmaceuticals

Bioiberica Receives Frost & Sullivan's 2025 European New Product Innovation Award for Clinically Validated Native Type II Collagen

The recognition highlights Bioiberica's science-led innovation, clinical differentiation, and manufacturing excellence in the European innovative collagen market. SAN ANTONIO, Feb. 18, 2026 /PRNewswire/ -- Frost & Sullivan

2026-02-18 18:00 6248

Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (b...

2026-02-18 05:54 6963

Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage

Headlines: * Delivers up to 2× higher sensitivity than stainless steel microflow columns, lowering detection and quantitation limits across high-throughput bioseparations, DMPK, and 'omics applications.1  * Uses up to 75% less sample than 2.1 mm I.D. columns, conserving precious materials su...

2026-02-17 21:00 5727

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003

SUZHOU, China, Feb. 14, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, for the treatment of ...

2026-02-14 20:58 10934

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial partnerships in South Korea and Vietnam. NEW TAIPEI CITY, Feb. 13, 2026 /PRNewswire/...

2026-02-13 08:00 11733

Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort® Enteral Solution, Human Milk-Based Product in Japan

* Clinigen obtained approval for Prolacta's "PreemieFort® Enteral Solution", a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the "Nutritional management of neonates and infants presenting with weight gain failure such as very low birth weight (VLBW) in...

2026-02-12 20:00 5543

ArisGlobal Announces XDI NavaX Data Intelligence, Three New Agents, and NavaX Translation

MADRID, Feb. 11, 2026 /PRNewswire/ -- ArisGlobal , an AI-first technology company at the forefront of Life Sciences and creator ofLifeSphere®,

2026-02-11 16:55 5538

Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development

-   Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies. -   In NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once...

2026-02-11 07:15 7189

IRBM Reports Breakthrough in Zika Virus Drug Discovery

ROME, Feb. 10, 2026 /PRNewswire/ -- IRBM, a leader in early drug discovery research, has announced a major scientific breakthrough with the discovery of a novel and potent allosteric inhibitor targeting the Zika virus (ZIKV) protease (NS2B-NS3). The findings, published inNature Communications (do...

2026-02-10 19:00 6080

ArrayPatch Announces First Close of €3M Seed Round to Advance ITZ-DerMap™ for Treatment of Nail Fungus

CORK, Ireland, Feb. 10, 2026 /PRNewswire/ -- ArrayPatch Ltd, a biotech company developing innovative microneedle-based therapeutics, today announced the first close of its €3 million seed funding round, to advance its lead program ITZ-DerMap™, a novel therapeutic designed for the treatment of ...

2026-02-10 16:01 4650

'Made in India - The story of Desh Bandhu Gupta, Lupin and Indian Pharma' Book Launched in Mumbai

MUMBAI, India, Feb. 9, 2026 /PRNewswire/ -- Made in India, written by Sundeep Khanna and Manish Sabharwal, traces three remarkable journeys: the rise of India's pharma industry, the birth and evolution of Lupin (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and the extraordinar...

2026-02-09 20:36 5380

CEVA ANNOUNCES STRATEGIC LEADERSHIP CHANGES IN ASIA-PACIFIC AND CHINA

LIBOURNE, France, Feb. 9, 2026 /PRNewswire/ -- Ceva Animal Health (Ceva), the world's fifth-largest animal health company operating in 110 countries, is implementing strategic organisational changes across Asia Pacific (APAC) and China to accelerate growth and drive operat...

2026-02-09 14:00 6806

Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer

CHENGDU, China, Feb. 6, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application for its TROP2-directed ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) has been approv...

2026-02-06 17:00 7142

Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis

SHANGHAI, Feb. 6, 2026  /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China's National Medical Products...

2026-02-06 13:10 6990

Precision for Medicine Broadens Global Footprint with Singapore Office Opening

Singapore Office Expands APAC Presence to Seven Locations, Delivering Enhanced Local Expertise and Global Scale BETHESDA, Md., Feb. 6, 2026 /PRNewswire/ -- Precision for Medicine (Precision), a global leader in biomarker-driven clinical research and development, has announced the opening of...

2026-02-06 08:50 2174

World's First Serum-Free Iterative Rabies Vaccine from AIM Successfully Passes On-Site Registration Inspections and Is Imminent for Launch

HONG KONG, Feb. 6, 2026 /PRNewswire/ -- Poised to Fill the Global Market Gap, the Serum-Free Iterative Rabies Vaccine Approaches a Critical Milestone in Commercialization. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on February 5 that its wholly-owned subsidiary AIM Rong...

2026-02-06 07:30 7858

Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas

MUMBAI, India, Feb. 6, 2026 /PRNewswire/ -- Piramal Critical Care, Inc. (PCC), an overseas subsidiary of Piramal Pharma Limited, and Blue-Zone Technologies Ltd. (Blue-Zone) announced an agreement to collaborate on full lifecycle technology to capture and recycle waste anaesthetic gases. By combi...

2026-02-06 01:04 8044

Sore Back After Pre-New Year Cleaning? Herbalgy's "Wellness Declutter" Method Shares 3 Tips to Sweep Away Pain for a Light, Energetic New Year

HONG KONG, Feb. 5, 2026 /PRNewswire/ -- As Lunar New Year approaches, many households dive into their annual deep cleaning, hoping to start the year in a fresh, orderly environment. However, intensive cleaning in a short period—repeated bending, squatting, kneeling, or lifting, can quickly lead t...

2026-02-05 22:38 6742

Moleac is pleased to announce that NeuroAiD™II has been awarded Gold accreditation by Empowered By Evidence.

SINGAPORE, Feb. 5, 2026 /PRNewswire/ -- This recognition reflects the robust clinical evidence supporting NeuroAiD™II, as well as the uniqueness of its formulation, the rigour of its manufacturing, reproducibility, and quality control, highlighting its reliability and value in supporting neurolog...

2026-02-05 11:48 8209

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive ...

2026-02-05 08:17 5790
12345678 ... 185